SPEAKER PROFILES Tuesday 24 March 2020 - KEMRI (KWTRP) - University of ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
3rd Annual Network Meeting
SPEAKER PROFILES
Tuesday 24 March 2020 - KEMRI (KWTRP)
Professor Philip Bejon
Programme Director, KEMRI, Kenya
My research career has primarily been within an overseas research programme in Kenya (i.e. the
KEMRI-Wellcome Trust Research Programme, where I am now the Director). I first came to Kenya
in 2002 to conduct Phase I and IIb clinical trials of a candidate malaria vaccine based on viral
vectors, working between the Jenner at University of Oxford and KEMRI-Wellcome. I returned to
Oxford in 2006 to complete specialist clinical training and to work as a senior fellow in the NIHR
Oxford Biomedical Research Centre in 2009 working on bone infection. I led further trials of GSK’s candidate malaria
vaccine “RTS,S”, and returned to Kilifi on an MRC Clinician-Scientist Fellowship in 2013, working on heterogeneity of
malaria transmission. I became Executive Director of the KEMRI-Wellcome Trust Research Programme in September
2014. My current interests still include malaria vaccines, as well as Yellow Fever and Ebola vaccines, studies of malaria
transmission dynamics including genotyping and work on a human malaria challenge model to study acquired immunity.
Professor Adam Cunningham
Co-director of BactiVac, Professor of Functional Immunity, University of Birmingham, UK
Professor Adam Cunningham gained his PhD from Southampton University for studies on
antibody responses to Chlamydia pneumoniae. After a short-term position in The Gambia,
funded by the WHO, he had his first post-doctoral position in Birmingham studying the cell wall
of Mycobacterium tuberculosis. From here, he started work in Prof. Ian MacLennan's group
examining how antibody responses develop and are regulated. During this time, he incorporated the use of Salmonella
and its component antigens into this work, leading to an independent position as a RCUK Roberts Academic Fellow,
studying how immune responses develop to pathogens and vaccines. He was made Professor of Functional Immunity
in August 2011 and his research is focused on how adaptive immunity to pathogens and their component antigens are
induced, maintained and function. These studies help us understand why some responses are protective, whilst others
are not or can even be harmful.
Dr Georgina Drury
Research Development Manager, University of Birmingham, UK
BactiVac Management Oversight Board Member
Georgina (George) Drury has a research background in molecular genetics and DNA repair. She
left bench science research in 2012 to pursue a career in science policy and funding, and held
roles in UK Government Office for Science, the Biotechnology and Biological Sciences Research
Council (BBSRC) and the Medical Research Council (MRC). Whilst working for the MRC as Programme Manager for
Immunology and Vaccines, George developed a number of different funding calls to support more research in vaccine
R&D, including the call for the Global Challenges Vaccine Networks, that funds BactiVac. George also led on forming
the UK Government’s Vaccine Network which oversees a range of activities – including funding – for pandemic
preparedness. She now leads the Research Development team in the Medical School at the University of Birmingham,
developing and submitting grants to a range of UK funders. George is a member of the BactiVac Operations and
Management Boards and has represented BactiVac at a World Health Organisation meeting on Group A
Streptococcus.
Page 1 of 9 v1
Dr Dorcas Kamuya
Chair Health Systems Research and Ethics, KEMRI, Kenya
I am a Wellcome Trust Society & Ethics fellow, conducting empirical ethics research examining if
and how communities could be engaged on complex ethical topics, with bio-banking as a case
study. Alongside this, I co-lead three areas of scientific protocols on ethically complex topics, in
which, together with colleagues in the department, we are exploring ethical and social-cultural
issues in order to contribute to current discourses, address important knowledge gap, and inform policy and practice.
The three areas include the Human Infection Studies (HIS), Neuro-developmental studies; and community and public
engagement. I am the current chair of the Health Systems Research Ethics Department (HSRE) at the KEMRI-Wellcome
Trust Research Programme and are a member of several local and international networks, chair/co-lead several
collaborative research initiatives and strategically contribute to the KWTRP strategic management as a member of the
Heads of Scientific Department. I continue to attract increasing levels of competitive research funding involving
collaborative research. My research work is shared through a growing list of publications, presentations in many national
and international meetings and conferences. My PhD, awarded by the Open University, UK (2013), examined ethical
dilemmas for frontline research staff. I hold a Master in Public Health (health promotion) from London School of Hygiene
and Tropical, and a BSc. in Agricultural Economics from Egerton University, Kenya.
Professor Calman MacLennan
Director of BactiVac, Professor of Vaccine Immunology, University of Oxford, UK
Professor of Vaccine Immunology, University of Birmingham, UK
Senior Program Officer, Bacterial Vaccines Global Health - Enteric & Diarrheal Diseases,
Bill & Melinda Gates Foundation, USA
I am a clinician scientist from the University of Oxford and currently a Senior Program Officer
with responsibility for bacterial vaccines in the Enteric And Diarrheal Diseases at the Bill and Melinda Gates Foundation.
After qualifying in medicine from Oxford, I studied for a doctorate in neurosciences before developing an interest in
infectious disease immunology. This led to time overseas in Kenya and then Malawi investigating immunity to invasive
Salmonella disease. From 2010 to 2014, I was Head of the Exploratory Programme at the Novartis Vaccines Institute
for Global Health, in Siena, Italy. There my programme developed new vaccines against Salmonella, Shigella and
meningococcus, and contributed to the establishment of a new bacterial vesicle vaccine platform, known as
Generalized Modules for Membrane Antigens. Following a sabbatical at the Wellcome Trust Sanger Institute, I returned
to Oxford in 2015 at the Jenner Institute. Salmonella immunology continues to be a main focus of my research with
ongoing projects in Africa, and my group is currently engaged in developing a vaccine against gonorrhoea. I am an
honorary consultant immunologist at Oxford University Hospitals NHS Foundation Trust, a member of visiting faculty
at the Sanger Institute and Professor of Vaccine Immunology at the University of Birmingham. My role at Birmingham
increased in August 2017 with the launch of the MRC GCRF BactiVac network. I see bacterial vaccines as having huge
potential for global health benefit and am excited about the opportunities that BactiVac has to advance this area of
vaccinology.
Page 2 of 9 v1
Ms Noni Mumba
Head of Community Engagement, KEMRI
My background is in Health and Strategic Behaviour Change Communication, Social Marketing
and more recently Communication Engagement. My primary role involves developing best
practice strategies for the involvement of communities and publics in research work across the
different KWTRP sites, through innovative engagement initiatives. I am also responsible for
mentoring and building capacity of community liaison and research staff in community and public engagement.
Additionally, I play a role in the monitoring and evaluation of our engagement activities, including sharing lessons
learnt across the globe. I provide guidance in the development of public engagement grant proposals and support
implementation of funded initiatives.
My involvement in health, science and communities stems from over 10 years of health promotion experience in HIV,
Malaria and Child Health across Kenya. I am currently driven by an interest in how to develop meaningful interactions
between Researchers and Communities in LMICs: not only ensuring that community views and perspectives influence
the conduct of research, but also that communities can be inspired by researchers from the region, and scientists by
the lessons of quality communication and engagement.
Professor George Warimwe
Associate Professor of Vaccinology, Vaccines Theme Lead, KEMRI
I am a Kenyan veterinary surgeon with research interests are on viral infections that are
transmitted between humans and animals, focusing on their epidemiology in populations in
Africa and developing vaccines for their control. My vaccine research group exploits synergies in
human and livestock immunology to accelerate development of candidate vaccines for
deployment in humans and the respective animal hosts of infection. Using this approach we
have developed a novel Rift Valley Fever vaccine currently in advanced trials in livestock to be followed by human
phase I studies in 2020. We are also leading the evaluation of fractional Yellow Fever vaccines in East Africa to inform
policies to tackle global vaccine shortages. In addition, we have embarked on a large programme of work aiming to
characterise the endemicity, clinical features and viral genetic diversity of a wide range of arboviruses in coastal Kenya
in order to inform candidate vaccine target product profiles. I am a member of the International Veterinary
Vaccinology Network (IVVN) management board, and co-lead the Emergency Preparedness work package of NIHR’s
Global Health Research Unit Tackling Infections To Benefit Africa (TIBA).
Dr Seanette Wilson
Dr Seanette Wilson
Science & Innovation Group Leader: Planning and Implementation, The Biovac Institute
BactiVac Management Oversight Board Member
Dr Wilson obtained her PhD in synthetic organic chemistry at the University of Cape Town before
starting at The Biovac Institute as a Senior Product Development Scientist. Biovac is a vaccine
manufacturing and distribution company based in Cape Town, South Africa. Dr Wilson was responsible for the
development of purification and conjugation processes for a Haemophilus influenza type b (Hib) conjugate vaccine. She
became the Principal Investigator of successful pneumococcal conjugate vaccine development project funded by PATH
and in collaboration with Chendu Institute of Biological Products, based in China. Currently Dr Wilson is responsible for
Planning & Implementation within Science & Innovation as well as being the Project Lead for the development of a
multivalent Group b Streptococcus conjugate vaccine.
Page 3 of 9 v1
3rd Annual Network Meeting
SPEAKER PROFILES
Wednesday 25 March – Friday 27 March 2020
Professor Richard A Adegbola, FAS
Independent Consultant at RAMBICON, Lagos, Nigeria
Bactivac Network Advisory Board Member
Professor Richard Adegbola, FAS, is an Independent Consultant in Immunisation & Global Health at
RAMBICON, Lagos, Nigeria. He trained as a Microbiologist in Nigeria and in the UK and has worked in
diagnostic microbiology, academia, philanthropy and pharmaceutical industry, across three
continents gaining unique and varied experiences. The impact of his work at the MRC Unit in The Gambia, now part of
LSHTM, on Hib and pneumococcal diseases and vaccines is a matter of public record and is well recognized within the
field. He joined the Bill & Melinda Gates Foundation, Seattle, USA, from the MRC Unit and worked as a Senior Program Officer
and Lead for Pneumonia Clinical Studies. He also worked at GlaxoSmithKline Vaccines in Belgium as a Global Director for
Scientific Affairs & Public Health with focus on external engagement on paediatric vaccines and, a portfolio covering countries
in Africa and Asia. Richard Adegbola has achieved many recognitions of his work including an honorary Professorship at
the University of Leicester, election to Fellowships of the UK’s Royal College of Pathologists and Royal College of
Physicians, and the Nigerian Academy of Science. He is passionate about his work and the role of vaccination in
building healthy societies.
Richard Adegbola was a member of the World Health Organization’s Meningitis Vaccine Project Advisory Group and
was Vice Chair of the European and Developing Countries Clinical Trials Partnership Board. He is a member of the
WHO Africa Regional Immunisation Technical Advisory Group (RITAG) and serves as a member or Chair of several
international scientific advisory boards. He is a Trustee of the Expanded Civil Society Initiative on Immunisation in
Nigeria. He has written five book chapters and co-authored 237 articles in peer-reviewed journals.
Dr Martin Broadstock
Programme Manager for Immunology and Vaccines, Medical Research Council, UK
Martin joined the MRC as the programme manager for Immunology in Jan 2017; his patch includes
immunology, vaccines, the host-response to pathogens and autoimmunity. Martin has been heavily
involved in launching the five MRC/BBSRC funded Networks for Vaccine R&D together with MRCs
involvement in the UK Vaccine Network. Prior to joining the MRC, Martin was a senior research fellow at King's College
London, researching novel therapies for the treatment of dementia and Parkinson's disease. Martin gained his PhD in
pharmacology from King’s College London in 2006.
Page 4 of 9 v1
Professor Adam Cunningham
Co-director of BactiVac, Professor of Functional Immunity
University of Birmingham, UK
Professor Adam Cunningham gained his PhD from Southampton University for studies on antibody
responses to Chlamydia pneumoniae. After a short-term position in The Gambia, funded by the
WHO, he had his first post-doctoral position in Birmingham studying the cell wall of Mycobacterium tuberculosis. From
here, he started work in Prof. Ian MacLennan's group examining how antibody responses develop and are regulated.
During this time, he incorporated the use of Salmonella and its component antigens into this work, leading to an
independent position as a RCUK Roberts Academic Fellow, studying how immune responses develop to pathogens and
vaccines. He was made Professor of Functional Immunity in August 2011 and his research is focused on how adaptive
immunity to pathogens and their component antigens are induced, maintained and function. These studies help us
understand why some responses are protective, whilst others are not or can even be harmful.
Professor Daniela F Hozbor
Professor at the National University of La Plata, Principal Scientific Researcher (CONICET Group
Leader and Head of National Reference Laboratory of pertussis, Argentina
I am a Professor at the Faculty of Sciences of UNLP, Group Leader and Head of National Reference
Laboratory of pertussis in Argentina. I have been performing research on Bordetella for over 27 years,
including studies on antigen secretion, host response, epidemiology, diagnosis, and vaccine
development. In the last years we have published extensively on vaccine development. My experience is in
Microbiology, Molecular and Systems Biology, Bacterial Diagnostics, epidemiology and Vaccinology. I have published
76 articles, 1 article in teaching, 7 book chapters, 2 national patents (1 accepted, 1 pending), 1 international patent
(granted in US, pending in other countries), 1 manual of procedures for diagnosis of Bordetella pertussis, several
outreach work and 121 presentations at national and international conferences. I have supervised as director or co-
director 11 PhD theses and 2 MSc. Four additional PhD thesis supervisions are ongoing. I am PlosOne academic editor
and acted as reviewer for numerous scientific articles. I have also revised a great number of national and international
research projects. I have made numerous technical transfers to the public sectors, especially in human health area. I
have supervised outreach projects at the Faculty of Sciences, UNLP.
Dr Elizabeth Klemm
Project Officer, Wellcome Trust, UK
BactiVac Management Oversight Board Member
Elizabeth Klemm is a project officer in the vaccines group at the Wellcome Trust. She
leads a project to establish and promote the role that vaccines play in reducing
antimicrobial resistance. Previously she was a senior scientist at the Wellcome Sanger
Institute where she studied bacterial pathogens and antimicrobial resistance using next generation
sequencing, including characterizing the first outbreak of extensively drug-resistant typhoid fever. She has
published articles on bacterial pathogenesis, host adaptation, and immune evasion. Dr. Klemm completed
her doctorate at the Massachusetts Institute of Technology.
Page 5 of 9 v1
Dr Kirsty Le Doare
Professor of Global Health and Honorary Paediatric Infectious Diseases and Immunology
Consultant within the Paediatric Infectious Diseases Research Group at St. George’s,
University of London & MRC/UVRI &LSHTM Uganda Research Unit, Uganda
Dr Le Doare is currently based in Kampala, Uganda working with the MRC/UVRI
&LSHTM Uganda Research Unit, as well as with MUJHU, a partnership between Makarere University and
Johns Hopkins University. Her research interests are age-related immune responses to infectious diseases,
in particular to Group B-streptococcus (GBS). She is interested in improving our knowledge of how maternal
antibody in blood and breast milk is passed to babies and how this protects them from colonisation and
disease. Her laboratory focus is on harnessing these tools of nature to improve vaccines and prevention
strategies. Her interest in GBS extends from basic pathophysiology and innate immunity, through clinical
trials, to epidemiology and public health interventions aimed at reducing the morbidity and mortality due to
this severe disease. She leads the GBS assay standardisation and serocorrelates of protection initiative and is
part of the WHO task-force to defeat meningitis and develop the pathway for licensing the GBS vaccine. She
has close collaborations with groups both in the UK and overseas, and although primarily based in Uganda,
travels frequently to other African countries, and is currently involved in ongoing studies in various African
sites including South Africa and Mozambique. She is chief investigator for the PROGRESS and PREPARE
studies which aim to identify serocorrelates of protection and build capacity un Uganda for maternal vaccine
studies respectively.She is passionate about training the next generation of female scientists working in
Africa to improve maternal and child health. She receives funding from the Thrasher and the Bill and
Melinda Gates Foundations, EDCTP and BACTIVAC. The UKRI Future Leaders Fellowship award will be used
to develop a platform for maternal vaccination clinical trials in Uganda and investigate ways to improve
outcomes from infection in women and their infants during pregnancy and early life.
Professor Calman MacLennan
Director of BactiVac, Professor of Vaccine Immunology, University of Oxford, UK
Professor of Vaccine Immunology, University of Birmingham, UK
Senior Program Officer, Bacterial Vaccines Global Health - Enteric & Diarrheal Diseases,
Bill & Melinda Gates Foundation, USA
I am a clinician scientist from the University of Oxford and currently a Senior Program Officer
with responsibility for bacterial vaccines in the Enteric And Diarrheal Diseases at the Bill and
Melinda Gates Foundation. After qualifying in medicine from Oxford, I studied for a doctorate in neurosciences before
developing an interest in infectious disease immunology. This led to time overseas in Kenya and then Malawi
investigating immunity to invasive Salmonella disease. From 2010 to 2014, I was Head of the Exploratory Programme at
the Novartis Vaccines Institute for Global Health, in Siena, Italy. There my programme developed new vaccines against
Salmonella, Shigella and meningococcus, and contributed to the establishment of a new bacterial vesicle vaccine
platform, known as Generalized Modules for Membrane Antigens. Following a sabbatical at the Wellcome Trust Sanger
Institute, I returned to Oxford in 2015 at the Jenner Institute. Salmonella immunology continues to be a main focus of
my research with ongoing projects in Africa, and my group is currently engaged in developing a vaccine against
gonorrhoea. I am an honorary consultant immunologist at Oxford University Hospitals NHS Foundation Trust, a member
of visiting faculty at the Sanger Institute and Professor of Vaccine Immunology at the University of Birmingham. My role
at Birmingham increased in August 2017 with the launch of the MRC GCRF BactiVac network. I see bacterial vaccines as
having huge potential for global health benefit and am excited about the opportunities that BactiVac has to advance
this area of vaccinology.
Page 6 of 9 v1
Dr Ebrahim Mohamed
AVMI, Director Biovac, S&I Group Leader, South Africa
Ebrahim Mohamed is a Synthetic Organic Chemist by training with 15 years’ experience in
pharmaceuticals with expertise covering business development, product development, technology
transfers, process optimizations and cGMP. After completing his PhD from the University of Cape
Town in 2009, he joined the Science and Innovation (S&I) Department at the Biovac Institute
(BIOVAC) where he established his expertise in the development of glycoconjugate vaccines. As Group Leader he
currently manages all the CMC related activities with the Science and Innovation department. He has accumulated
experience in both inward and outward bound technology transfers of clinical vaccine candidates and commercial
products. His responsibilities have expanded further to include support to manufacturing operations at Biovac. In 2015
Ebrahim became a key member of the secretariat team of the African Vaccine Manufacturing Initiative (AVMI) where
he has played a pivotal part in assisting with the coordination of the AVMI Vaccine Manufacturing and Procurement in
Africa (VMPA) study. He was elected as a member of the board, representing the Southern African Region in 2016.
Ebrahim has published several publications in reputable peer-reviewed journals.
Professor Richard Moxon
Emeritus Professor of Paediatrics and a Professorial Fellow of Jesus College, University of
Oxford, UK
Richard Moxon is Emeritus Professor of Paediatrics and a Professorial Fellow of Jesus College,
University of Oxford. UK. His paediatric and research training was in the UK (1966-1969) and the
USA (1970-1974). He was Assistant and then Associate Professor of Paediatrics at Johns Hopkins
University in Baltimore (1974-1984), becoming the Eudowood Director of Pediatric Infectious Diseases in 1981 before
he was elected as Action Research Professor and Chairman of Paediatrics at Oxford University (1984 - 2008) and Head
of the Molecular Infectious Diseases Group in the Weatherall Institute of Molecular Medicine (1988-2008). He is a
Fellow of the UK Royal College of Paediatrics and Child Health and of the UK Academy of Medical Sciences and was
elected a Fellow of the Royal Society in 2007. His major research interests have been on the pathogenesis and
prevention of sepsis and meningitis caused by the bacteria Haemophilus influenzae and Neisseria meningitidis.
Dr Francis J. Ndowa
Specialist Venereologist-Dermatologist; Director, Skin & GU Medicine Clinic, Harare,
Zimbabwe
Dr Ndowa currently based in Zimbabwe as Director and Physician (Specialist Venereologist) at
the Skin & Genito-Urinary Medicine Clinic. He provides international consultancy on
surveillance and the control of sexually transmitted infections, containment of antimicrobial
resistance, in general, and in Neisseria gonorrhoeae, in particular. He currently is a member of the ReAct Toolbox
International Advisory Group on antimicrobial resistance. He is a member of the WHO RHR/HRP Scientific and
Technical Advisory Group. He served as a member of the WHO Strategic and Technical Advisory Group on
Antimicrobial Resistance from September 2013 to September 2016. He is the Regional Director of the Africa and
Middle East & North Africa Branch of the International Union against STIs (IUSTI). Dr Ndowa acquired his medical
degree at the University of Birmingham Medical School, UK, and has postgraduate diplomas in Venereology and
Dermatology from London, UK. He worked in the National Health Services in the UK, the Ministry of Health and Child
Care in Zimbabwe and then in Geneva from 1996 to 2012, based in the Joint United Nations Programme on HIV/AIDS
(UNAIDS) and the World Health Organization (WHO) working on Controlling Sexually Transmitted & Reproductive
Tract Infections until the age of mandatory retirement in 2012.
Page 7 of 9 v1
Professor Andrew Pollard
Professor of Paediatric Infection and Immunity, University of Oxford, UK
BactiVac Management Oversight Board Member
Andrew is Professor of Paediatric Infection and Immunity at the University of Oxford (in post since
2001). His research includes the design, development and clinical evaluation of vaccines including
those for meningococcal disease and enteric fever and leads studies using a human challenge model of (para)typhoid.
He runs surveillance for invasive bacterial diseases and studies the impact of pneumococcal vaccines in children in Nepal
and leads a project on burden and transmission of typhoid and co-leads typhoid vaccine impact studies at these sites.
He has supervised 23 PhD students and his publications include over 400 manuscripts and books on various topics in
paediatrics and infectious diseases. He chairs the UK Department of Health’s Joint Committee on Vaccination and
Immunisation and the European Medicines Agency scientific advisory group on vaccines and is a member of WHO’s
SAGE. He received the Bill Marshall award of the European Society for Paediatric Infectious Disease (ESPID) in 2013 and
the ESPID Distinguished Award for Education & Communication in 2015. He was elected to the Academy of Medical
Sciences in 2016.
Professor Samir K. Saha
Head of Microbiology Department, Bangladesh Institute of Child Health
Dhaka Shishu Hospital, Dhaka, Bangladesh
Executive Director, Child Health Research Foundation, Dhaka, Bangladesh
Dr. Samir K. Saha is the Professor and Head of the Department of Microbiology and the Executive
Director of The Child Health Research Foundation at the Bangladesh Institute of Child Health,
Dhaka Shishu Hospital in Dhaka, Bangladesh.
Dr. Saha was the first scientist from a developing country to receive the American Society for Microbiology (ASM)
award in 2017, for his outstanding research in Clinical Microbiology. Which was followed by Fellowship in the
American Academy of Microbiology. The same year he received the UNESCO Carlos J. Finlay Prize in Microbiology for
his contribution in the field of microbiology and helping the government of Bangladesh to make evidence based
decision on introduction of Hib and pneumococcal conjugate vaccine.
The November 2017 edition of National Geographic Magazine published "Here’s Why Vaccines Are So Crucial", an
article revolving around the need and impact of vaccines in society and vividly highlighted the lifelong dedication of Dr.
Saha's fight to beating pneumonia and other pneumococcal infections in Bangladesh. In the fall of 2019 Dr. Saha and
his team's publication in The Lancet received The Charles C. Shepard Science Award in the assessment category for
their outstanding contribution in public health.
Dr. Saha is currently a member of the National Immunization Technical Advisory Group (NiTAG) of the Government of
Bangladesh. He is also the member of WHO’s Technical Advisory Group (TAG) for i) invasive bacterial vaccine
preventable diseases and ii) Respiratory Syncytial Virus.
He has published more than 150 papers in peer-reviewed journals, mostly relating to childhood typhoid, pneumonia
and meningitis. Dr. Saha is conducting several multi-site and multi-country research projects supported by different
international funding organizations.
Page 8 of 9 v1
End-to-End Vaccinology Workshop
Friday 27 March 2020
Programme delivered by:
Dr Sanet Aspinall
Managing Director/Clinical Research Consultant
Arden Consulting (Pty) Ltd, South Africa
Sanet is a highly experienced Medical Science Research Executive, holds a PhD degree in
Virology and has amassed a life- time of academic, entrepreneurial and international executive
experience.
Dr Sanet Aspinall is currently the Founder of Ardent Consulting (Pty) Ltd, based in South Africa
and provides consulting and training services to Pharma, Biotechnology Companies, CROs,
NGOs, Foundations and the clinical research industry.
Current activities include services to the International Vaccine Institute and BMGF for Site
Preparation in Nepal to conduct a large Phase 3 Vaccine study, training in GCP, clinical trial
management, quality management and regulatory services to various organisations.
She was the Founder of the first private SMO company in South Africa, which was acquired in 2007 by Synexus, UK, the
world’s largest clinical research site network. Prior to setting up two clinical research companies in South Africa, she was
Professor in Virology and later Deputy Dean Research and Director for Research at the Medical University of Southern
Africa where she, amongst other activities, worked with several pharma and vaccine companies to assist them in their
research and development programmes.
Her experience spans over 200 clinical studies of early and late stage development in different therapeutic areas
including vaccines (HBV, Tetra and Pentavalent vaccines, Rota, Influenza, RSV, and HIV) and infectious diseases.
Sanet served as a previous member of the South African Medicines Control Council and the Biologics Committee and as
a previous Member of Steering Committees on Vaccine studies for PATH and WHO.
Dr Aspinall is the author and co-author of numerous scientific articles and presentations at scientific meetings.
Page 9 of 9 v1
You can also read
